MOTS-C

MOTS-c is a mitochondrial-derived peptide central to metabolic research. It is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR, approximately 2,122 Da) encoded within the 12S rRNA region of mitochondrial DNA, and in preclinical models it activates AMPK to improve insulin sensitivity and shift substrate use toward fatty-acid oxidation. JCSG.org supplies research-grade Body Pharm MOTS-c to United Arab Emirates laboratories for laboratory research use only — not for human or veterinary use.

Our peptides

Body Pharm MOTS-C 32 Pen — a 32-dose pen delivering the mitochondrial-derived 16-amino-acid peptide for metabolic and exercise research.

Body Pharm MOTS-C 10 — a 10 mg vial of Body Pharm MOTS-c, a mitochondrial-derived peptide for metabolic research.

Live AED pricing is shown in the buy box on each product page.

Key takeaways

• MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded in mtDNA that activates AMPK to improve insulin sensitivity in preclinical models.
• All human efficacy data remain preclinical or early-phase; no large-scale randomised controlled trials have been completed.
• The AMPK mechanism links MOTS-c conceptually to other cellular-energy research compounds but distinguishes it from growth-hormone secretagogues.
• MOTS-c is supplied strictly as a research chemical and is not a registered medicine.
• JCSG.org stocks Body Pharm research-grade MOTS-c alongside the adjacent NAD+ research overview.

What is MOTS-c? A plain-language definition

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) with the sequence MRWQEMGYIFYPRKLR and a molecular mass of approximately 2,122 Da. It is encoded within the 12S rRNA region of mitochondrial DNA rather than the nuclear genome. Lee and colleagues first described it in Cell Metabolism in 2015.

That mitochondrial origin sets MOTS-c apart from the vast majority of signalling peptides in human biology, which are translated from nuclear-encoded mRNAs and processed through the endoplasmic reticulum. Mitochondrial DNA carries only 37 genes, and for decades the 12S rRNA locus was assumed to code exclusively for ribosomal RNA. Identifying a small open reading frame within that locus — one producing a functional peptide with systemic metabolic activity — reframed mitochondria as endocrine-capable organelles that can synthesise and export signalling molecules independent of the nuclear genome.

Why the mtDNA origin matters

Because MOTS-c is transcribed inside the mitochondrion, its expression is sensitive to mitochondrial copy number, heteroplasmy and the bioenergetic state of the cell. These properties distinguish it mechanistically from nuclear-encoded metabolic regulators, and they are why researchers studying related mitochondrial-support compounds such as NAD+ treat MOTS-c as conceptually adjacent. It behaves nothing like a growth-hormone secretagogue that acts through pituitary GHRH receptors.

How MOTS-c is encoded in mitochondrial DNA

The human mitochondrial genome is a 16,569-base-pair circular, double-stranded DNA molecule encoding 37 genes: 13 protein-coding sequences for oxidative phosphorylation subunits, 22 transfer RNAs and 2 ribosomal RNAs. MOTS-c is translated from a small open reading frame nested inside the 12S rRNA gene, a locus historically annotated as purely structural RNA. That dual-use coding is biologically unusual: the same nucleotide stretch yields both ribosomal RNA and a bioactive peptide, which explains why MOTS-c sat undetected for decades.

MOTS-c sits within a small but expanding class of mitochondrial-derived peptides that includes humanin (encoded in 16S rRNA) and the SHLP1–6 series. Conservation of these open reading frames across vertebrates is high, and rodent findings are treated as translationally informative for human physiology despite the absence of large human trials.

The MOTS-c mechanism: from mitochondria to AMPK

MOTS-c signals metabolic stress by translocating from the mitochondria to the nucleus and activating AMPK, the cell's master energy sensor. AMPK in turn drives glucose uptake, fatty-acid oxidation and mitochondrial biogenesis. This nuclear translocation step distinguishes MOTS-c from most peptide hormones, which act exclusively through cell-surface receptors and second messengers.

The pathway runs in discrete stages. MOTS-c is translated from the 12S rRNA open reading frame inside the mitochondrion, then released into the cytoplasm. Under glucose restriction, exercise or other energetic stress, it moves into the nucleus — a translocation that is itself AMPK-dependent, creating a feed-forward loop. Once nuclear, it modulates stress-response transcriptional networks. AMPK is phosphorylated at Thr172 via an LKB1-dependent route, as an AMP/ATP-ratio shift mimics energetic stress. Active AMPK then increases GLUT4-mediated glucose uptake in skeletal muscle, upregulates fatty-acid beta-oxidation, suppresses mTORC1-driven anabolic signalling and promotes mitochondrial biogenesis through PGC-1alpha.

AMPK is also the principal effector of first-line metabolic agents, which is why MOTS-c and those drugs produce overlapping metabolic signatures — MOTS-c reaches the same node by a different route, as an endogenous, exercise-responsive AMPK activator. This is a mechanistic observation, not a claim of clinical equivalence: no human efficacy data exist.

What researchers study

MOTS-c as an exercise mimetic

An exercise mimetic is a compound that reproduces the cellular and metabolic adaptations of physical activity without the mechanical workload. MOTS-c qualifies mechanistically because it activates AMPK at Thr172 through an LKB1-dependent, energy-stress-like route — the same molecular node engaged by contraction-induced AMP/ATP shifts in working skeletal muscle. Zheng and colleagues (2023) characterise MOTS-c as reproducing key transcriptional signatures of endurance exercise in skeletal muscle, with AMPK inhibition partially abolishing those effects. The 2023 reviews are explicit that human translational data remain limited and that the exercise-mimetic profile is a preclinical and early-stage concept. No evidence supports MOTS-c as a replacement for structured exercise.

Insulin sensitivity

MOTS-c improves insulin sensitivity in preclinical models by activating AMPK in skeletal muscle, driving GLUT4 translocation, increasing glucose uptake and reducing circulating glucose. AMPK-driven translocation bypasses the need for intact insulin signalling. The foundational Lee et al. 2015 work established canonical mouse regimens that remain the reference preclinical benchmarks cited in later reviews. All efficacy data through 2026 derive from rodent studies or small early-phase human work; no large randomised trials in metabolic-disease populations have been completed.

Obesity, muscle and bone

Gao and colleagues (2023) consolidate four domains where MOTS-c shows preclinical activity. In high-fat-diet mice it prevents weight gain without altering food intake, raising energy expenditure and shifting substrate use toward fat oxidation. It is described as an exercise-responsive myokine that enhances mitochondrial biogenesis via AMPK–PGC-1alpha. In bone, it promotes osteoblast proliferation and mineralisation while suppressing osteoclastogenesis. Of these domains, insulin resistance carries the strongest evidence and bone the weakest, and all remain preclinical-dominant. Online marketing frequently extends these mechanisms into anti-ageing and lifespan claims; no human randomised trial data support those claims.

The Body Pharm MOTS-C formats

Two formats are stocked for UAE researchers:

Format	Reserve	Suits
Body Pharm MOTS-C 32 Pen	32 doses	Extended metabolic and exercise-research arms
Body Pharm MOTS-C 10	10 mg vial	Dose-ranging and shorter in vitro work

The 32-dose pen carries a larger reserve, reducing re-order cycles and holding a single lot number across a longer study. The 10 mg vial suits variable-concentration work where a vial-and-syringe workflow gives more titration flexibility. Request a batch-specific Certificate of Analysis confirming purity and sequence identity before ordering either.

Handling and storage

In research settings MOTS-c is reconstituted in sterile water for injection, 0.9% saline or bacteriostatic saline. Lyophilised material is held at −20 °C (colder for storage beyond several months). Reconstituted peptide is kept at 2–8 °C for one to two weeks, or aliquoted and re-frozen to avoid freeze-thaw cycles. Log the lot number and CoA reference in the institutional reagent register for traceability. No standardised human dosing protocol exists in peer-reviewed literature; figures circulated on supplier sites are extrapolated from rodent work and should not be treated as clinical guidance.

Regulatory context in the UAE

MOTS-c is not a registered medicine and is supplied by JCSG.org strictly as a research chemical for in vitro and preclinical laboratory use. The "research chemical" or "for research use only" label is a commercial convention, not a regulatory category — it signals that the material has not been assessed for human safety, efficacy or quality. Importation and domestic distribution fall under the relevant national health-authority oversight, and research-use or free-zone labelling does not exempt an entity from that oversight or from customs review. Confirm classification with your institutional compliance officer before raising a purchase order. This page is not legal or medical advice.

Range placement

MOTS-c sits with the mitochondrial and metabolic peptides in the JCSG.org UAE catalogue. Its closest mechanistic neighbour is NAD+, which acts upstream of sirtuin-mediated mitochondrial regulation and is complementary rather than redundant. Adjacent research tools include the tissue-repair peptides BPC-157 and TB500, the growth-hormone-axis peptides CJC-1295 and ipamorelin, and the metabolic lead compound retatrutide.

Frequently asked questions